A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Ditching Invading DNA: Bacteria and archaea protect themselves from invasive foreign nucleic acids through an RNA-mediated adaptive immune system called CRISPR (clustered regularly interspaced short palindromic repeats)/CRISPR-associated (Cas). Jinek et al. (p. 816 , published online 28 June; see the Perspective by Brouns ) found that for the type II CRISPR/Cas system, the CRISPR RNA (crRNA) as well as the trans-activating crRNA—which is known to be involved in the pre-crRNA processing—were both required to direct the Cas9 endonuclease to cleave the invading target DNA. Furthermore, engineered RNA molecules were able to program the Cas9 endonuclease to cleave specific DNA sequences to generate double-stranded DNA breaks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Repurposing bacterial “CRISPR” systems to facilitate RNA-guided cleavage of complementary DNA has revolutionized the field of gene editing in mammalian cells 1–4.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To realize this promise, the development of CRISPR-Cas9 for genome editing offers a simpler technology that has been adopted widely due to the ease of programming its DNA binding and modifying capabilities.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recombinant expression and purification of EvoCas9–1 paired with chemically synthesized Evo-generated single guide RNA (sgRNA) exhibited comparable in vitro cleavage activity to SpCas9 paired with the canonical SpCas9 sgRNA”
From Sequence modeling and design from molecular to genome scale with Evo (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cas9 can create DNA cleavage at desired genomic positions that are guided by precise base pairing between sgRNA and DNA, adjacent to a protospacer-adjacent motif (PAM) (Jinek et al., 2012; Cho et al., 2013; Cong et al., 2013; Wang et al., 2016a).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Jinek et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CRISPR/Cas9 is a class of ribonucleoprotein complexes formed by a Cas9 protein and a single guide RNA (sgRNA) (Jinek et al., 2012; Cho et al., 2013; Cong et al., 2013; Wang et al., 2016a).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Jinek et al., 2012
Experimental — accuracy not yet measured
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
CRISPR RNA Maturation by Trans-Encoded Small RNA and Host Factor RNase III
Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011) · Nature · doi:10.1038/nature09886 · Cited by 2,563
Self-citationSmall CRISPR RNAs Guide Antiviral Defense in Prokaryotes
Brouns, S. J. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuis, R. J. H., Snijders, A. P. L., Dickman, M. J., Makarova, K. S., Koonin, E. V., & van der Oost, J. (2008) · Science · doi:10.1126/science.1159689 · Cited by 2,460
Evolution and classification of the CRISPR–Cas systems
Makarova, K. S., Haft, D. H., Barrangou, R., Brouns, S. J. J., Charpentier, E., Horvath, P., Moineau, S., Mojica, F. J. M., Wolf, Y. I., Yakunin, A. F., et al. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2577 · Cited by 2,331
Self-citationThe CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA
Garneau, J. E., Dupuis, M.-È., Villion, M., Romero, D. A., Barrangou, R., Boyaval, P., Fremaux, C., Horvath, P., Magadán, A. H., & Moineau, S. (2010) · Nature · doi:10.1038/nature09523 · Cited by 2,328
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
A TALE nuclease architecture for efficient genome editing
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1755 · Cited by 2,098
Targeting DNA Double-Strand Breaks with TAL Effector Nucleases
Christian, M., Cermak, T., Doyle, E. L., Schmidt, C., Zhang, F., Hummel, A., Bogdanove, A. J., & Voytas, D. F. (2010) · Genetics · doi:10.1534/genetics.110.120717 · Cited by 1,869
Cited by
Items 1,201–1,285 of 1,285
Holmgaard, A. B., Askou, A. L., Jensen, E. G., Alsing, S., Bak, R. O., Mikkelsen, J. G., & Corydon, T. J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.032 · Cited by 36
Genetic interaction mapping informs integrative structure determination of protein complexes
Braberg, H., Echeverria, I., Bohn, S., Cimermancic, P., Shiver, A., Alexander, R., Xu, J., Shales, M., Dronamraju, R., Jiang, S., et al. (2020) · Science · doi:10.1126/science.aaz4910 · Cited by 37
“CRISPR-Cas9 genome editing (79) has proven highly effective for high-throughput genetic interactionmapping inmammalian cells (80, 81).”
BackgroundGlycoengineering Chinese hamster ovary cells: a short history
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37
CRISPR/Cas9-targeted removal of unwanted sequences from small-RNA sequencing libraries
Hardigan, A. A., Roberts, B. S., Moore, D. E., Ramaker, R. C., Jones, A. L., & Myers, R. M. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz425 · Cited by 37
“New genome- and epigenome-editing tools based on repurposing the CRISPR/Cas9 (clustered regularly interspersed short palindromic repeats/Cas9) bacterial immune system have many potential uses (27,28).”
BackgroundZhou, Y., Luo, K., Liang, L., Chen, M., & He, X. (2023) · Nature Methods · doi:10.1038/s41592-023-02017-4 · Cited by 34
“The discovery of CRISPR and development of the CRISPR–Cas9 system for genomic editing has revolutionized biology 1,2 .”
BackgroundComparison of CRISPR/Cas Endonucleases for in vivo Retinal Gene Editing
Li, F., Wing, K., Wang, J.-H., Luu, C. D., Bender, J. A., Chen, J., Wang, Q., Lu, Q., Nguyen Tran, M. T., Young, K. M., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.570917 · Cited by 34
Yu, L., Su, W., Fey, P. D., Liu, F., & Du, L. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00293 · Cited by 33
Wörle, E., Newman, A., D’Silva, J., Burgio, G., & Grohmann, D. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac767 · Cited by 32
Applications of the CRISPR/Cas system beyond gene editing
Anton, T., Karg, E., & Bultmann, S. (2018) · Biology Methods and Protocols · doi:10.1093/biomethods/bpy002 · Cited by 32
“The most commonly used point mutations to inactivate either of the two nuclease domains are D10A and H840A for RuvC and HNH, respectively [16, 17, 21, 25, 26].”
BackgroundWörle, E., Newman, A., Burgio, G., & Grohmann, D. (2022) · doi:10.1101/2022.03.15.484427 · Cited by 32
New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
Oostveen, R. F., Khera, A. V., Kathiresan, S., Stroes, E. S. G., Fitzgerald, K., Harms, M. J., Oakes, B. L., & Kastelein, J. J. P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317963 · Cited by 31
Anti‐CRISPR proteins targeting the CRISPR‐Cas system enrich the toolkit for genetic engineering
Liu, Q., Zhang, H., & Huang, X. (2020) · The FEBS Journal · doi:10.1111/febs.15139 · Cited by 31
Gene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
“133–135 One of the earliest targets of CRISPR/Cas system-mediated gene therapy has been retinal diseases and both in vitro and in vivo studies have confirmed its efficiency for use in this field of medicine.”
Oxytocin, vasopressin and social behavior in the age of genome editing: a comparative perspective
Boender, A. J., & Young, L. J. (2020) · Hormones and Behavior · doi:10.1016/j.yhbeh.2020.104780 · Cited by 30
“The CRISPR/Cas9 system consists of a guide RNA (gRNA) homologous to the target gene that guides the Cas9, an RNA guided endonuclease, to any genomic locus flanked by the sequence NGG (Cong et al., 2013; Jinek et al., 2012).”
BackgroundPitt, C., Paschen, J., Kietzmann, J., Pitt, L. F., & Pala, E. (2023) · Australasian Marketing Journal · doi:10.1177/18393349211044175 · Cited by 30
“A good recent example of this concerns what is arguably the single most significant technological advance of the 21st century to date, CRISPR (“clusters of regularly interspaced short palindromic repeats”) (see Doudna & Charpentier, 2014; Jinek et al., 2012).”
BackgroundCRISPRi-ART enables functional genomics of diverse bacteriophages using RNA-binding dCas13d
Adler, B. A., Al-Shimary, M. J., Patel, J. R., Armbruster, E. G., Colognori, D., Charles, E. J., Miller, K. V., Lahiri, A., Cui, M. L., Oromí-Bosch, A., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-01935-7 · Cited by 30
“The simple observation of ‘phage restric-tion’ 54 led to the discovery and mechanistic understanding of numerous biotechnological tools such as restriction enzymes and CRISPR systems 55–59 .”
Self-citationRNA targeting and cleavage by the type III-Dv CRISPR effector complex
Schwartz, E. A., Bravo, J. P. K., Ahsan, M., Macias, L. A., McCafferty, C. L., Dangerfield, T. L., Walker, J. N., Brodbelt, J. S., Palermo, G., Fineran, P. C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47506-y · Cited by 30
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Racharaks, R., Arnold, W., & Peccia, J. (2021) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2021.106315 · Cited by 29
Pittis, A. A., Goh, V., Cebrian-Serrano, A., Wettmarshausen, J., Perocchi, F., & Gabaldón, T. (2020) · Nature Communications · doi:10.1038/s41467-020-17705-4 · Cited by 29
Bzhilyanskaya, V., Ma, L., Liu, S., Fox, L. R., Whittaker, M. N., Meis, R. J., Choi, U., Lawson, A., Ma, M., Theobald, N., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj6779 · Cited by 28
“The conventional PAM for Streptococcus pyogenes Cas9 (SpCas9) is NGG, where “N” is any nucleotide ( 31 – 33 ).”
BackgroundModelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?
McKnight, C. L., Low, Y. C., Elliott, D. A., Thorburn, D. R., & Frazier, A. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147730 · Cited by 27
Li, J., Wu, P., Cao, Z., Huang, G., Lu, Z., Yan, J., Zhang, H., Zhou, Y., Liu, R., Chen, H., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113765 · Cited by 26
Hamilton, P. J., Lim, C. J., Nestler, E. J., & Heller, E. A. (2018) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7774-1_5 · Cited by 28
Podobnik, M., Frohnhöfer, H. G., Dooley, C. M., Eskova, A., Nüsslein-Volhard, C., & Irion, U. (2020) · Nature Communications · doi:10.1038/s41467-020-20021-6 · Cited by 26
Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells
Holzinger, A., & Abken, H. (2022) · Pharmacology · doi:10.1159/000525052 · Cited by 24
Hu, C., Myers, M. T., Zhou, X., Hou, Z., Lozen, M. L., Nam, K. H., Zhang, Y., & Ke, A. (2024) · Molecular Cell · doi:10.1016/j.molcel.2023.12.034 · Cited by 24
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
CRISPR-Cas9 in agriculture: Approaches, applications, future perspectives, and associated challenges
Adhikari, P., & Poudel, M. (2020) · Malaysian Journal of Halal Research · doi:10.2478/mjhr-2020-0002 · Cited by 23
“CRISPR-cas9 tracrRNA+ crRNA Streptococcus pyogenes Cas9 NGG [10] CRISPR-cpf1 Single RNA Prevotella and Fracisella Cas1, Cas2, Cas4 YTN [34] Ng-Ago Single RNA Natronobacterium gregoryi Argonaute Not required [30]”
BackgroundInfluentialA single plasmid based CRISPR interference in Synechocystis 6803 – A proof of concept
Kirtania, P., Hódi, B., Mallick, I., Vass, I. Z., Fehér, T., Vass, I., & Kós, P. B. (2019) · PLOS ONE · doi:10.1371/journal.pone.0225375 · Cited by 22
“An inactivated Cas9, termed as deadCas9 (dCas9), was developed which preserves the specific binding capacity to DNA targets of Cas9, with a complete loss of its nuclease activity [2].”
BackgroundCarvalho, C., Lemos, L., Antas, P., & Seabra, M. C. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1270561 · Cited by 21
Development and application of prime editing in plants
Tingting, L., Jinpeng, Z., Xi, Y., Kejian, W., Yuchun, R., & Chun, W. (2023) · Rice Science · doi:10.1016/j.rsci.2023.07.005 · Cited by 21
Methods for in vitro CRISPR/CasRx-Mediated RNA Editing
Chuang, Y.-F., Wang, P.-Y., Kumar, S., Lama, S., Lin, F.-L., & Liu, G.-S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.667879 · Cited by 21
“CRISPR/Cas-type II RNA-guided nucleases, including Streptococcus pyogenes Cas9 (SpCas9), have been extensively explored and demonstrated to possess excellent DNA editing capabilities (Jinek et al., 2012).”
BackgroundDissecting mammalian immunity through mutation
Siggs, O. M. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2014.8 · Cited by 20
Genome Editing of Veterinary Relevant Mycoplasmas Using a CRISPR-Cas Base Editor System
Ipoutcha, T., Rideau, F., Gourgues, G., Arfi, Y., Lartigue, C., Blanchard, A., & Sirand-Pugnet, P. (2022) · Applied and Environmental Microbiology · doi:10.1128/aem.00996-22 · Cited by 19
“The typical CRISPR-Cas9 tool is based on the Cas9 nuclease and is guided to specific loci by single guide RNAs (sgRNAs) (24).”
MethodLewis, M., Prouzet‐Mauléon, V., Lichou, F., Richard, E., Iggo, R., Turcq, B., & Mahon, F. (2020) · Cancer Medicine · doi:10.1002/cam4.3231 · Cited by 19
CRISPR-assisted strategies for futuristic phytoremediation
Patel, H., Shakhreliya, S., Maurya, R., Pandey, V. C., Gohil, N., Bhattacharjee, G., Alzahrani, K. J., & Singh, V. (2022) · Assisted Phytoremediation · doi:10.1016/b978-0-12-822893-7.00006-9 · Cited by 19
(2024) · doi:10.1038/s41467-024-51695-x · Cited by 19
CRISPR/cas-mediated genome editing in sorghum — recent progress, challenges and prospects
Parikh, A., Brant, E. J., Baloglu, M. C., & Altpeter, F. (2021) · In Vitro Cellular & Developmental Biology - Plant · doi:10.1007/s11627-021-10215-y · Cited by 18
Castillo (2016) · doi:10.25100/cm.v47i4.2856 · Cited by 18
Industry chain and challenges of microalgal food industry-a review
Chen, Y., Liang, H., Du, H., Jesumani, V., He, W., Cheong, K.-L., Li, T., & Hong, T. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2145455 · Cited by 18
“When this foreign DNA invades again, the cells will cut the foreign DNA through base complementary pairing (Jinek et al. 2012).”
BackgroundRodent Genetic Models of Ah Receptor Signaling
Wilson, R. H., & Bradfield, C. A. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1955916 · Cited by 16
“AHR mutations induced by gene editing Within the past decade, the generation of model systems has been aided by the advancement of CRISPRbased gene editing techniques (Gasiunas et al. 2012; Jinek et al. 2012; Cong et al. 2013; Mali et al. 2013).”
MethodCelotti, M., Derks, L. L. M., van Es, J., van Boxtel, R., Clevers, H., & Geurts, M. H. (2024) · STAR Protocols · doi:10.1016/j.xpro.2024.103189 · Cited by 17
BoostMEC: predicting CRISPR-Cas9 cleavage efficiency through boosting models
Zarate, O. A., Yang, Y., Wang, X., & Wang, J.-P. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04998-z · Cited by 17
Hybrid multitask learning reveals sequence features driving specificity in the CRISPR/Cas9 system
Vora, D. S., Yadav, S., & Sundar, D. (2023) · Biomolecules · doi:10.3390/biom13040641 · Cited by 17
A general genome editing strategy using CRISPR lipid nanoparticle spherical nucleic acids
Han, Z., Huang, C., Luo, T., & Mirkin, C. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2426094122 · Cited by 17
Current advances in CRISPR-Cas-mediated gene editing and regulation in cyanobacteria
Dong, Z., Chen, L., Wang, Y., Sun, T., & Zhang, W. (2024) · Blue Biotechnology · doi:10.1186/s44315-024-00009-3 · Cited by 16
“CRISPR-Cas9 and CRISPR-Cas12a are the main CRISPR-Cas systems used for DNA fragment editing [39, 40].”
BackgroundLi, J., Tuma, J., Han, H., Kim, H., Wilson, R. C., Lee, H. Y., & Murthy, N. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102118 · Cited by 16
Pelizaeus–Merzbacher disease: on the cusp of myelin medicine
Elitt, M. S., & Tesar, P. J. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.03.005 · Cited by 16
Development of a base editor for convenient and multiplex genome editing in cyanobacteria
Li, X.-D., Liu, L.-M., Xi, Y.-C., Sun, Q.-W., Luo, Z., Huang, H.-L., Wang, X.-W., Jiang, H.-B., & Chen, W. (2024) · Communications Biology · doi:10.1038/s42003-024-06696-3 · Cited by 14
Okada, K., Aoki, K., Tabei, T., Sugio, K., Imai, K., Bonkohara, Y., & Kamachi, Y. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac100 · Cited by 14
CRISPR/Cas9 genome surgery for retinal diseases
Xu, C. L., Park, K. S., & Tsang, S. H. (2018) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.05.001 · Cited by 14
Hermann, D. M., Bacigaluppi, M., Bassetti, C. L., Bassotti, G., Boltze, J., Chan, A., Dalkara, T., Denes, A., Diez-Tejedor, E., Dodel, R., et al. (2025) · Exploration of Neuroscience · doi:10.37349/en.2025.1006106 · Cited by 13
“Gene cloning by CRISPR/Cas9, chemogenetic and optogenetic tools meanwhile allow manipulating defined neuronal cell types and pathways with high precision [19, 20].”
Chromatin structure and context-dependent sequence features control prime editing efficiency
Kim, S., Yuan, J. B., Woods, W. S., Newton, D. A., Perez-Pinera, P., & Song, J. S. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1222112 · Cited by 12
“One of the most powerful gene editing tools available today is the complex of clustered regularly interspaced short palindromic repeats (CRISPRs) with CRISPR-associated protein 9 (Cas9) (Jinek et al., 2012; Cong et al., 2013; Jinek et al., 2013; Mali et al., 2013).”
Genetic physical unclonable functions in human cells
Li, Y., Bidmeshki, M. M., Kang, T., Nowak, C. M., Makris, Y., & Bleris, L. (2022) · Science Advances · doi:10.1126/sciadv.abm4106 · Cited by 12
Guo, T., Zheng, F., Zeng, Z., Yang, Y., Li, Q., She, Q., & Han, W. (2019) · RNA Biology · doi:10.1080/15476286.2019.1642725 · Cited by 11
Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07293-w · Cited by 10
Creeth, R., Thompson, A., & Kevei, Z. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1589431 · Cited by 9
The history, landscape, and outlook of human cell line authentication and security
Harbut, E., Makris, Y., Pertsemlidis, A., & Bleris, L. (2024) · SLAS Discovery · doi:10.1016/j.slasd.2024.100194 · Cited by 8
Christi, K., Hudson, J., & Egan, S. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127729 · Cited by 8
Genome Editing for the β-Hemoglobinopathies
Porteus, M. H. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-7299-9_8 · Cited by 8
Focused ultrasound‐mediated APOE4 knockdown in mouse brain
Zheng, K., Tsitsos, F. N., Batts, A. J., Ji, R., Nuriel, T., Konofagou, E. E., & Leong, K. W. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70464 · Cited by 8
CRISPR off-target analysis platforms
Xu, C. L., Ruan, M. Z., Ragi, S. D., & Tsang, S. H. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-2651-1_26 · Cited by 6
The CRISPR/Cas9 System for Crop Improvement: Progress and Prospects
Leong, K.-Y. B., Chan, Y.-H., Abdullah, W. M. A. N. W., Lim, S.-H. E., & Lai, K.-S. (2018) · Next Generation Plant Breeding · doi:10.5772/intechopen.75024 · Cited by 5
“The three major components of the immune system are the protospacer-containing CRISPR RNA (crRNA), transactivating crRNA (tracrRNA) and the Cas9 endonuclease [27, 30].”
Guan, K., Ocampo, R. F., Matheus Carnevali, P. B., Castelle, C. J., Gonzalez-Osorio, L., Castanzo, D. T., Thomas, N. C., Brothers, M., Dangerfield, T. L., Hooper, M. M., et al. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01788-6 · Cited by 5
Bamundo, M., Palumbo, S., D'Auria, L., Missero, C., & Di Girolamo, D. (2024) · Current Protocols · doi:10.1002/cpz1.70056 · Cited by 4
“The CRISPR/Cas systems are commonly categorized into two classes based on differences in structure and organization of the Cas genes (Jinek et al., 2012).”
Structural basis of a dual-function type II-B CRISPR–Cas9
Hibshman, G. N., & Taylor, D. W. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf585 · Cited by 4
“Among these systems, the Cas9 endonuclease quickly gained attention for its widespread applications in genome engineering [ 2–4 ].”
Genome editing and opportunities for trait improvement in pearl millet
Panda, D., Baig, M. J., & Molla, K. A. (2024) · Pearl Millet in the 21st Century · doi:10.1007/978-981-99-5890-0_7 · Cited by 4
Esquerra‐Ruvira, B., Baquedano, I., Ruiz, R., Fernandez, A., Montoliu, L., & Mojica, F. J. M. (2023) · Microbial Biotechnology · doi:10.1111/1751-7915.14266 · Cited by 4
“, 2008) and a transactivating crRNA (tracrRNA) (Deltcheva et al., 2011; Jinek et al., 2012).”
BackgroundMethodInfluentialEngineering the cardiac tissue microenvironment
Ronan, G., Bahcecioglu, G., Aliyev, N., & Zorlutuna, P. (2024) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ad0ea7 · Cited by 4
CoCoNuTs are a diverse subclass of Type IV restriction systems predicted to target RNA
Bell, R. T., Sahakyan, H., Makarova, K. S., Wolf, Y. I., & Koonin, E. V. (2024) · eLife · doi:10.7554/elife.94800.3 · Cited by 3
Omura, S. N., Nakagawa, R., Kajimoto, S., Okazaki, S., Ishiguro, S., Mori, H., Onishi, K., Kashiwakura, Y., Hiramoto, T., Horinaka, K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71626-2 · Cited by 2
“To comprehensively assess the effect of the N413A/R420A double mutations on the target speci fi city, we examined the in vitro DNA cleavage activities of SaCas9 and SaCas9-NNG toward DNA substrates containing a mismatch at positions 1 – 21.”
Structural insights into Cas9-mediated prespacer selection in CRISPR-Cas adaptation
Gaizauskaite, U., Tamulaitiene, G., Silanskas, A., Gasiunas, G., Siksnys, V., & Sasnauskas, G. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.01.022 · Cited by 2
Evolution of prime editing systems: move forward to the treatment of hereditary diseases
Volodina, O. V., Fabrichnikova, A. R., Anuchina, A. A., Mishina, O. S., Lavrov, A. V., & Smirnikhina, S. A. (2025) · Current Gene Therapy · doi:10.2174/0115665232295117240405070809 · Cited by 1
CoCoNuTs: A diverse subclass of Type IV restriction systems predicted to target RNA
Bell, R. T., Sahakyan, H., Makarova, K. S., Wolf, Y. I., & Koonin, E. V. (2023) · doi:10.1101/2023.07.31.551357 · Cited by 1
Wenson, L., Heldin, J., Martin, M., Erbilgin, Y., Salman, B., Sundqvist, A., Schaal, W., Sandbaumhüter, F. A., Jansson, E. T., Chen, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62512-4 · Cited by 1
Suzuki, T., & Bono, H. (2025) · Database · doi:10.1093/database/baaf022 · Cited by 1
A dendritic guidance receptor functions in both ligand dependent and independent modes
Reddy, A. R., Machera, S. J., Cook, Z. T., Deng, H., Nawrocka, W. I., Özkan, E., & Shen, K. (2025) · PLOS Genetics · doi:10.1371/journal.pgen.1011942 · Cited by 1
“We used clustered regularly interspersed short palindromic repeats (CRISPR)-Cas9 genome editing to generate a non-binding receptor mutant allele [29,30].”
Suzuki, T., & Bono, H. (2024) · doi:10.1101/2024.10.16.617154 · Cited by 1
Kinetic mechanism for fidelity of CRISPR-Cas9 variants
Hecht, A. D., & Igoshin, O. A. (2025) · bioRxiv · doi:10.1101/2025.01.27.634389
Fundamental Methods in Molecular Biology
Ijaz, S., & Hassan, S. (2026) · Molecular Biology Methods · doi:10.1007/978-981-92-2642-9_1
(2025) · doi:10.1016/j.jbc.2025.110701
RAC2 orchestrates immune cell actin remodeling and migration
Berthiaume Fox, K. A., Galvin, E. R., Gurtner, G. C., & Chen, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1917716
CoCoNuTs: A diverse subclass of Type IV restriction systems predicted to target RNA
Bell, R. T., Sahakyan, H., Makarova, K. S., Wolf, Y. I., & Koonin, E. V. (2024) · doi:10.7554/elife.94800.2
(2016) · doi:10.13918/j.issn.2095-8137.2016.4.191
“A key feature of Cas9 recognition and cleavage is based on the PAM near the 3' terminal of the target sequence (Jinek et al., 2012; Sternberg et al., 2014).”
BackgroundMethodInfluential
Metadata
- Authors
- Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E.
- Affiliations
- Howard Hughes Medical Institute (HHMI), University of California, Berkeley, CA 94720, USA.
- University of Vienna (AT)
- Umeå Centre for Microbial Research (SE)
- University of California, Berkeley (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Chylinski, Krzysztof
- Doudna, Jennifer A.
- Charpentier, Emmanuelle
- Venue
- Science
- Published
- 2012-08-17
- Volume
- 337
- Issue
- 6096
- Pages
- 816-821
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6286148
- OpenAlex
- W2045435533
- Semantic Scholar
- 68d962effe5520777791bd6ec8ffa4b963ba4f38
- Cited by
- 17,116
- References
- 48
- Citations by year
- 2026: 1083 · 2025: 1512 · 2024: 1602 · 2023: 1572 · 2022: 1795 · 2021: 1793 · 2020: 1577 · 2019: 1344 · 2018: 1255 · 2017: 1141 · 2016: 1018 · 2015: 680 · 2014: 467 · 2013: 231 · 2012: 29
- FWCI
- 180.75
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- CRISPR/Cas9, sequence-specific DNA cleavage, DNA double-strand breaks
- MeSH terms
- Bacteriophages, Base Sequence, Molecular Sequence Data, Nucleic Acid Conformation, Plasmids, RNA, Streptococcus pyogenes, Deoxyribonucleases, Type II Site-Specific, DNA Cleavage, DNA Breaks, Double-Stranded, Inverted Repeat Sequences
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.